- home
- about us
- Investment Approach
- Client Service Approach
- Market Analysis Summary
- Mission Statement
- Value Proposition
- Team Biographies
- Firm ADV PDFs
- Form CRS
- Firm Brochure-Part 2A of Form ADV
- Brochure Supplement Amit Stavinsky
- Brochure Supplement Frank Parks
- Brochure Supplement Dominick Savo
- Brochure Supplement Richard Mason
- Brochure Supplement Joe Estes
- Brochure Supplement Jonathan Ezra
- Statement Of Financial Strength
- Job Opportunities
- Letter to Clients
- member log-in
- contact us
Latest News about psilocybin therapy
Recent news which mentions psilocybin therapy
From Benzinga
Utah Hospitals Will Soon Provide Psilocybin And MDMA Therapy For Mental Health Conditions
March 25, 2024
From Benzinga
Psyched: New Evidence Shows Psilocybin As Anxiety Therapy, Open-Source Learning For Therapists, Enveric's Licensing Deals And More
March 04, 2024
From Benzinga
Washington Doctor Vs. DEA For Lawful Use Of Psilocybin To Treat Terminally Ill Patients
February 14, 2024
Tickers
NEWS
From Benzinga
From Benzinga
Canada's Ongoing Struggle For Access To Natural Psilocybin As A Therapeutic Nabs Business Support
February 15, 2023
Tickers
TRUFF
From Benzinga
Canadian Psychedelics Company Launches Take-Home Psilocybin Trial For Some 300 Participants
February 01, 2023
From Benzinga
From Benzinga
2023 Could Be Make Or Break For Psychedelics In Missouri, This GOP Lawmaker Is Pushing For Change
January 09, 2023
From Benzinga
What Happened With Psychedelics In The Last Year? 11 Key News Items, The Sector's Performance & Takeaways
January 03, 2023
From Benzinga
From Benzinga
First-Ever Clinical Trial On Magic Mushroom Therapy For Autism's Genetic Cause Receives Approval
December 27, 2022
From Benzinga
Canada: Fed Guidelines For Psychedelic Therapy, Quebec Treatment Costs, Access And Magic Mushrooms Dispensaries
December 21, 2022
From Benzinga
Potential Road To At-Home Psychedelics Use Permits: Low Dosing's Positive Outcomes In Phase 1 Trial
December 12, 2022
From Benzinga
Magic Mushrooms Tested For Treating Type II Bipolar Disorder, Check Out Results So Far
December 12, 2022
Tickers
CMPS
From Benzinga
DEA's Consistent Denial Of Psilocybin Access For Terminally Ill Being Challenged Again
October 27, 2022
From Benzinga
From Benzinga
Cannabis & Psychedelics As Effective Adjunct Medicine To Breast Cancer Therapy? Studies Say Yes
September 30, 2022
From Benzinga
Why Magic Mushrooms Are Emerging As Major Part Of Public Discourse: What Science Is Saying
September 22, 2022
Tickers
CMPS
From Benzinga
Why Magic Mushrooms Are Emerging As Major Part Of Public Discourse: The Legal Situation
September 19, 2022
From Benzinga
Major Psychedelics Firm Is Studying Magic Mushrooms To Treat Meth Addiction
September 16, 2022
Tickers
RVVTF
From Benzinga
Mindset Pharma Meets With UK Regulator: Is A Phase 1 Trial Getting Close?
September 14, 2022
Tickers
MSSTF
From Benzinga
Psychedelics Companies Are Teaming Up To Offer Access Veterans
September 13, 2022
From Benzinga
Cathie Wood's Psychedelics Fund ARK Analyzes The Sector's Present & Future And Likes What It Sees
September 06, 2022
Tickers
ATAI
From Benzinga
From Benzinga
The Case For Psilocybin Therapy And Depression
January 30, 2022
From Benzinga
ATAI Life Sciences Announces New Program To Discover Next-Generation Mental Health Treatments
January 27, 2022
Tickers
ATAI
From Benzinga
Psilocybin Therapy Combined With SSRI Antidepressants Is Possible, COMPASS Study Confirms
December 13, 2021
Tickers
CMPS
From Benzinga
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.